Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ENTX with free AI briefings, catalyst countdowns, and dilution alerts.

ENTX · Entera Bio Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$265.9M Cash on Hand
146.9mo Cash Runway
Follow ENTX by email Get an email when ENTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ENTX, unsubscribe in one click. Privacy

📣 What ENTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Parathyroid Hormone Hypoparathyroidism Phase 2 · NCT03516773 Completed
EBP11 Hypoparathyroidism Phase 1 · NCT05965167 Completed
EBP11-F1 Hypoparathyroidism Phase 1 · NCT05965167 Completed
EBP11-F2 Hypoparathyroidism Phase 1 · NCT05965167 Completed
EBP11-F4 Hypoparathyroidism Phase 1 · NCT05965167 Completed
EBP11-F5 Hypoparathyroidism Phase 1 · NCT05965167 Completed
EBP22 Hypoparathyroidism Phase 1 · NCT05965167 Completed

Also used in these trials (approved or third-party drugs, not ENTX's own candidates): Colesevelam, Teriparatide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ENTX holds $265.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $5.4M/quarter from operations, an estimated runway of 146.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ENTX files for a raise →

👥 Who Owns ENTX

Insiders 1.3% Other 5%+ holders 18.9% Institutions (38 holders) 52.9% Public and other holders 26.9%
HolderTypeShares% of sharesAs of
BVF PARTNERS L P/IL Institution (13G, 5%+) 17,225,121 9.89% 2026-07-28
TCG Crossover GP III, LLC 5%+ holder (13G) 12,254,901 7.04% 2026-07-28
Vivo Opportunity, LLC 5%+ holder (13G) 11,817,401 6.79% 2026-07-28
Spruce Street Capital LP Institution (13G, 5%+) 11,213,455 6.44% 2026-09-30
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 8,861,763 5.09% 2026-10-23
Miranda Jayne Toledano
Chief Executive Officer, Director · +1.20M options
Insider 847,135 0.49% 2026-07-14
Gerald M Lieberman
Director · +90,523 options
Insider 344,654 0.20% 2026-01-01
Sean Ellis
Director · +102,014 options
Insider 208,132 0.12% 2026-08-07
Gregory Burshtein
Chief of R&D · +380,000 options
Insider 189,033 0.11% 2026-05-07
Dana Yaacov-Garbeli
Chief Financial Officer · +270,000 options
Insider 171,441 0.10% 2026-05-07
Hillel Galitzer
Chief Operating Officer · +200,000 options
Insider 163,566 0.09% 2026-05-07
Haya Taitel
Director · +62,014 options
Insider 119,269 0.07% 2026-08-07

Share count 174,137,771 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ENTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.